COMPLETE GENOMICS INC Form 8-K June 01, 2011

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 1, 2011

COMPLETE GENOMICS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction

001-34939 (Commission 20-3226545 (IRS Employer

of incorporation) File Number) Identification Number)

2071 Stierlin Court

Mountain View, California 94043

(Address of principal executive offices, including Zip Code)

Registrant s telephone number, including area code: (650) 943-2800

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On June 1, 2011, Complete Genomics, Inc. issued a press release announcing the closing of its underwritten public offering of 6,325,000 shares of its common stock at a public offering price of \$12.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 825,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. A copy of the press release is filed as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits. (d) Exhibits.

Exhibit No. Description

99.1 Press release dated June 1, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 1, 2011 COMPLETE GENOMICS, INC.

By: /s/ Ajay Bansal Ajay Bansal

Chief Financial Officer

EXHIBIT INDEX

Exhibit No. Description

99.1 Press release dated June 1, 2011